» Articles » PMID: 15201348

Botulinum Toxin in Clinical Practice

Overview
Date 2004 Jun 18
PMID 15201348
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Botulinum toxin, the most potent biological toxin, has become a powerful therapeutic tool for a growing number of clinical applications. This review draws attention to new findings about the mechanism of action of botulinum toxin and briefly reviews some of its most frequent uses, focusing on evidence based data. Double blind, placebo controlled studies, as well as open label clinical trials, provide evidence that, when appropriate targets and doses are selected, botulinum toxin temporarily ameliorates disorders associated with excessive muscle contraction or autonomic dysfunction. When injected not more often than every three months, the risk of blocking antibodies is slight. Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications.

Citing Articles

Neurotoxin-Derived Optical Probes for Elucidating Molecular and Developmental Biology of Neurons and Synaptic Connections : Toxin-Derived Optical Probes for Neuroimaging.

Bijjam R, Shorter S, Bratt A, OLeary V, Ntziachristos V, Ovsepian S Mol Imaging Biol. 2024; 26(6):912-925.

PMID: 39348040 PMC: 11634926. DOI: 10.1007/s11307-024-01954-6.


Patient Characteristics and Real-World Use of Botulinum Toxins for the Treatment of Cervical Dystonia, Blepharospasm, and Hemifacial Spasm.

Hast M, Kong A, Desai S, Back S, Syed S, Holmes J Toxins (Basel). 2024; 16(8).

PMID: 39195772 PMC: 11359877. DOI: 10.3390/toxins16080362.


Model-based interspecies interpretation of botulinum neurotoxin type A on muscle-contraction inhibition.

Ryu H, Kwak S, Park M, Yun H Biopharm Drug Dispos. 2024; 45(4-6):190-200.

PMID: 39031599 PMC: 11687410. DOI: 10.1002/bdd.2398.


Botulinum toxin therapy for isolated first dorsal interosseous muscle pain and hypertrophy: A case report.

Rahimibarghani S, Aghaghazvini L, Shirzad N, Fateh H Clin Case Rep. 2024; 12(7):e9094.

PMID: 38915929 PMC: 11194289. DOI: 10.1002/ccr3.9094.


Intragastric Botulinum Toxin Injection and Botulism: An Alarm for Clinicians.

Mojtahedzadeh M, Najmeddin F, Pourheidar E, Najafi A, Bahman R, Yousefi-Mazhin E Case Rep Crit Care. 2024; 2024:8183127.

PMID: 38716476 PMC: 11074901. DOI: 10.1155/2024/8183127.


References
1.
Naumann M, Hamm H, Lowe N . Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol. 2002; 147(6):1218-26. DOI: 10.1046/j.1365-2133.2002.05059.x. View

2.
Hsiung G, Das S, Ranawaya R, Lafontaine A, Suchowersky O . Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002; 17(6):1288-93. DOI: 10.1002/mds.10252. View

3.
Dolimbek B, Jankovic J, Atassi M . Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002; 31(3-4):247-62. DOI: 10.1081/imm-120016244. View

4.
Foran P, Mohammed N, Lisk G, Nagwaney S, Lawrence G, Johnson E . Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem. 2002; 278(2):1363-71. DOI: 10.1074/jbc.M209821200. View

5.
Jankovic J, Vuong K, Ahsan J . Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003; 60(7):1186-8. DOI: 10.1212/01.wnl.0000055087.96356.bb. View